Targeting β-cell cyclic 3′5′ adenosine monophosphate for the development of novel drugs for treating type 2 diabetes mellitus. A rewiew

Journal of Pharmacy and Pharmacology

Volumn 56, Issue 12, 2004, Pages 1477-1492

  Furman, Brian ^a   Pyne, Nigel ^a   Flatt, Peter ^b   O'Harte, Finbarr ^b  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 [2 [3 (CYCLOPENTYLOXY) 4 METHOXYPHENYL] 2 PHENYLETHYL]PYRIDINE; 6 (5,6 DIMETHOXYBENZO[B]THIEN 2 YL) 4,5 DIHYDRO 5 METHYL 3(2H) PYRIDAZINONE; ADENYLATE CYCLASE; AROFYLLINE; ATIZORAM; CILOMILAST; CILOSTAMIDE; CYCLIC AMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; DIPEPTIDYL PEPTIDASE IV; DIPYRIDAMOLE; ENOXIMONE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; MILRINONE; N CYCLOHEXYL 4 (1,2 DIHYDRO 2 OXO 6 QUINOLYLOXY) N (2 HYDROXYETHYL)BUTYRAMIDE; PEPTIDE; PHOSPHODIESTERASE INHIBITOR; PICLAMILAST; ROLIPRAM; SCH 51866; SIGUAZODAN; SILDENAFIL; UNCLASSIFIED DRUG; VINPOCETINE; ZAPRINAST; ZARDAVERINE;

ADIPOCYTE; CELL DIFFERENTIATION; CELL GROWTH; CELL SURVIVAL; ENZYMATIC DEGRADATION; ENZYME ACTIVITY; ENZYME INHIBITION; HORMONE RELEASE; HUMAN; INSULIN RELEASE; LIVER CELL; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PROTEIN DEGRADATION; REVIEW;

EID: 10044294739     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/0022357044805     Document Type: Review

References (186)

1. Ahmad, M., Abdel-Wahab, Y. H. A., Tate, R., Flatt, P. R., Pyne, N. J., Furman, B. L., (2000a) Effect of type-selective inhibitors on cyclic nucleotide phosphodiesterase activity and insulin secretion in the clonal insulin secreting cell line BRIN-BD11. Br. J. Pharmacol. 129: 1228-1234
2. Ahmad, M., Flatt, P. R., Furman, B. L., Pyne, N. J. (2000b) The role of cyclic GMP-inhibited cAMP-specific phosphodiesterase (PDE3) in regulating clonal BRIN-BD11 insulin secreting cell survival. Cellular Signalling 12: 541-548
3. Ahren, B., Holst, J. J., Martensson, H., Balkan, B. (2000) Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. Eur. J. Pharmacol. 404: 239-245
4. Ahren, B., Simonsson, E., Larsson, H., Landin-Olsson, M., Torgeirsson, H., Jansson, P. A., Sandqvist, M., Bavenholm, P., Efendic, S., Eriksson, J. W., Dickinson, S., Holmes, D. (2002) Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 25: 869-875
5. Al-Majed, H. T., Jones, P. M., Persaud, S. J., Sugden, D., Huang, G. C., Amiel, S., Whitehouse, B. J. (2004) ACTH stimulates insulin secretion from MIN6 cells and primary mouse and human islets of Langerhans. J. Endocrinol. 180: 155-166
6. Andersen, H. U., Mauricio, D., Karlsen, A. E., Mandrup-Poulsen, T., Nielsen, J. H., Nerup, J. (1996) Interleukin-1 beta-induced nitric oxide production from rat isolated islets is modulated by D-glucose and 3-isobutyl-1-methyl xanthine. Eur. J. Endocrinol. 134: 251-259
7. Balkan, B., Kwasnik, L., Miserendino, R., Holst, J. J., Li, X. (1999) Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia 42: 1324-1331
8. Bastard, J. P., Pieroni, L., Hainque, B. (2000) Relationship between plasma plasminogen activator inhibitor 1 and insulin resistance. Diabetes Metab. Res. Rev. 16: 192-201
9. Benes, C., Roisin, M. P., Van Tan, H., Creuzet, C., Miyazaki, J., Fagard, R. (1998) Rapid activation and nuclear translocation of mitogen-activated protein kinases in response to physiological concentration of glucose in the MIN6 pancreatic beta cell line. J. Biol. Chem. 273: 15507-15513
10. Benes, C., Poitout, V., Marie, J.-C., Martin-Perez, J., Roisin, M. P., Fagard, R. (1999) Mode of regulation of the extracellular signal-regulated kinases in the pancreatic β-cell line MIN6 and their implication in the regulation of insulin gene transcription. Biochem. J. 340: 219-225
11. Besay, E., Prud'homme, G. J. (2001) Inhibitors of phosphodiesterase isoforms III or IV suppress islet-cell nitric oxide production. Lab. Invest. 81: 1109-1117
12. Brown, J. C., Pederson, R. A., Jorpes, E., Mutt, V. (1969) Preparation of highly active enterogastrone. Can. J. Physiol. Pharmacol. 47: 113-114
13. Brubaker, P. L., Anini, Y. (2003) Direct and indirect mechanisms regulating secretion of glucagon-like peptide-1 and glucagon-like peptide-2. Can. J. Physiol. Pharmacol. 81: 1005-1012
14. Bryer-Ash, M., Cheung, A., Pederson, R. A. (1994) Feedback regulation of glucose-dependent insulinotropic polypeptide (GIP) secretion by insulin in conscious rats. Regul. Pept. 51: 101-109
15. Burcelin, R., Dolci, W., Thorens, B. (1999) Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analog of glucagon-like peptide-1. Metabolism 48: 252-258
16. Burkey, B. F., Li, X., Bolognese, L., Russell, M., Wang, P. R., Villhauer, E. B., Hughes, T. E. (2002) Combination treatment of a DPP-IV inhibitor NVP-LAF237 with pioglitazone completely normalized glucose tolerance in adult obese Zucker rats. Diabetes 51(Suppl. 2): A1383
17. Buteau, J., Roduit, R., Susini, S., Prentki, M. (1999) Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells. Diabetologia 42: 856-864
18. Buteau, J., Foisy, S., Joly, E., Prentki, M. (2003) Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor. Diabetes 52: 124-132
19. Calleja, V., Ruiz Enriquez, P., Filloux, C., Peraldi, P., Baron, V., Van Obberghen, E. (1997) The effect of cyclic adenosine monophosphate on the mitogen-activated protein kinase pathway depends on both the cell type and the type of tyrosine kinase-receptor. Endocrinology 138: 1111-1120
20. Capito, K., Hedeskov, C. J., Thams, P. (1986) Cyclic AMP phosphodiesterase activity in mouse pancreatic islets. Effects of calmodulin and phospholipids. Acta Endocrinol. 111: 533-538
21. Chang, A. M., Jakobsen, G., Stuns, J., Smith, M. J., Bloem, C. J., An, B., Galecki, A., Halter, J. B. (2003) The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes 52: 1786-1791
22. Cheng, H. C., Abdel-Ghany, M., Zhang, S., Pauli, B. U. (1999) Is the Fischer 344/CRJ rat a protein-knock-out model for dipeptidyl peptidase IV-mediated lung metastasis of breast cancer? Clin. Exp. Metastasis 17: 609-615
23. Chou, J. Z., Place, G. D., Waters, D. G., Kirkwood, J. A., Bowsher, R. R. (1997) A radioimmunoassay for LY315902, an analog of glucagon-like insulinotropic peptide, and its application in the study of canine pharmacokinetics. J. Pharm. Sci. 86: 768-773
24. Clapham, J. C., Widerspin, A. F. (2001) Cloning of dog heart PDE1A-a first detailed characterization at the molecular level. Gene 268: 165-171
25. Corbin, J. D., Francis, S. H. (1999) Cyclic GMP phosphodiesterase-5: target of sildenafil. J. Biol. Chem. 274: 13729-13732
26. Creutzfeldt, W. O., Kleine, N., Willms, B., Ørskov, C., Holst, J. J., Nauck, M. A. (1996) Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients. Diabetes Care 19: 580-586
27. De La Tour, D., Halvorsen, T., Demeterco, C., Tyrberg, B., Itkin-Ansari, P., Loy, M., Yoo, S. J., Hao, E., Bossie, S., Levine, F. (2001) Beta-cell differentiation from a human pancreatic cell line in vitro and in vivo. Mol. Endocrinol. 15: 476-483
28. Deacon, C. F., Knudsen, L. B., Madsen, K., Wiberg, F. C., Jacobsen, O., Holst, J. J. (1998) Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity. Diabetologia 41: 271-278
29. Deacon, C. F., Danielsen, P., Klarskov, L., Olesen, M., Holst, J. J. (2001) Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs. Diabetes 50: 1588-1597
30. Deacon, C. F., Wamberg, S., Bie, P., Hughes, T. E., Holst, J. J. (2002) Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs. J. Endocrinol. 172: 355-362
31. Delmeire, D., Flamez, D., Hinke, S. A., Cali, J. J., Pipeleers, D., Schuit, F. (2003) Type VIII adenylyl cyclase in rat beta cells: coincidence signal detector/generator for glucose and GLP-1. Diabetologia 46: 1383-1393
32. Ding, W. Q., Dong, M., Ninova, D., Holicky, E. L., Stegall, M. D., Miller, L. J. (2003) Forskolin suppresses insulin gene transcription in islet beta-cells through a protein kinase A-independent pathway. Cell Signal 15: 27-35
33. Doyle, M. E., Greig, N. H., Holloway, H. W., Betkey, J. A., Bernier, M., Egan, J. M. (2001) Insertion of an N-terminal 6-aminohexanoic acid after the 7 amino acid position of glucagon-like peptide-1 produces a long-acting hypoglycemic agent. Endocrinology 142: 4462-4468
34. Drews, G., Debuyser, A., Henquin, J. C. (1994) Significance of membrane repolarization and cAMP changes in mouse pancreatic B-cells for the inhibition of insulin release by galanin. Mol. Cell Endocrinol. 105: 97-102
35. Drucker, D. J. (2003) Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 26: 2929-2940
36. Drucker, D. J., Philippe, J., Mojsov, S., Chick, W. L., Habener, J. F. (1987) Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc. Natl. Acad. Sci. USA 84: 3434-3438
37. Eckel, R. H., Fujimoto, W. Y., Brunzell, J. D. (1979) Gastric inhibitory polypeptide enhanced lipoprotein lipase activity in cultured preadipocytes. Diabetes 28: 1141-1142
38. Edmondson, S. D., Mastracchio, A., He, J., Chung, C. C., Forrest, M. J., Hofsess, S., MacIntyre, E., Metzger, J., O'Connor, N., Patel, K., Tong, X., Tola, M. R., Van der Ploeg, L. H., Varnerin, J. P., Fisher, M. H., Wyvratt, M. J., Weber, A. E., Parmee, E. R. (2003) Benzyl vinylogous amide substituted aryldihydropyridazinones and aryldimethylpyrazolones as potent and selective PDE3B inhibitors. Bioorg. Med. Chem. Lett. 13: 3983-3987
39. Edvell, A., Lindstrom, P. (1999) Initiation of increased pancreatic islet growth in young normoglycemic mice (Umea +/?). Endocrinology 140: 778-783
40. Egan, J. M., Clocquet, A. R., Elahi, D. (2002) The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J. Clin. Endocrinol. Metab. 87: 1282-1290
41. Egan, J. M., Meneilly, G. S., Elahi, D. (2003) Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes. Am. J. Physiol. Endocrinol. Metab. 4: E1072-E1079
42. Ehses, J. A., Pelech, S. L., Pederson, R. A., Mclntosh, C. H. (2002) Glucose-dependent insulinotropic polypeptide activates the Raf-Mek1/2-ERK1/2 module via a cyclic AMP/cAMP-dependent protein kinase/Rap1-mediated pathway. J. Biol. Chem. 277: 37088-37097
43. Eissele, R., Koop, H., Arnold, R. (1990) Effect of glucagon-like peptide-1 on gastric somatostatin and gastrin secretion in the rat. Scand. J. Gastroenterol. 25: 449-454
44. Elahi, D., Meneilly, G. S., Minaker, K. L., Rowe, J. W., Andersen, D. K. (1986) Regulation of hepatic glucose production by gastric inhibitory polypeptide in man. Can. J. Physiol. Pharmacol. 65: A18
45. El-Metwally, M., Shafiee-Nick, R., Pyne, N. J., Furman, B. L. (1997) The effect of selective phosphodiesterase inhibitors on plasma insulin concentrations and insulin secretion in vitro in the rat. Eur. J. Pharmacol. 324: 227-232
46. Elrick, L. J., Docherty, K. (2001) Phosphorylation-dependent nucleocytoplasmic shuttling of pancreatic duodenal homeobox-1. Diabetes 500: 2244-2252
47. Fehmann, H. C., Habener, J. F. (1992) Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells. Endocrinology 130: 159-166
48. Fehmann, H. C., Göke, R. (1995) Characterization of GIP(1-30) and GIP(1-42) as stimulators of proinsulin gene transcription. Peptides 16: 1149-1152
49. Feinle, C., Chapman, I. M., Wishart, J., Horowitz, M. (2002) Plasma glucagon-like peptide-1 (GLP-I) responses to duodenal fat and glucose infusions in lean and obese men. Peptides 23: 1491-1495
50. Filipsson, K., Holst, J. J., Ahren, B. (2000) PACAP contributes to insulin secretion after gastric glucose gavage in mice. Am. J. Physiol. Regul. Integr. Camp, Physiol. 279: R424-R432
51. Filipsson, K., Kvist-Reimer, M., Ahren, B. (2001) The neuropeptide pituitary adenylate cyclase-activating polypeptide and islet function. Diabetes 50: 1959-1969
52. Fisher, D. A., Smith, J. F., Pillar, J. S., St Denis, S. H., Cheng, J. B. (1998) Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase. J. Biol. Chem. 273: 15559-15564
53. Furman, B. L., Pyne, N. J. (1990) Islet phosphodiesterase isoenzymes and insulin secretion. Diabetic Med. 7: 19A
54. Gault, V. A., Parker, J. C., Harriott, P., Flatt, P. R., O'Harte, F. P. M. (2002a) Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide, GIP(3-42), is a GIP receptor antagonist in vivo. J. Endocrinol. 175: 525-533
55. 1-modified enzyme resistant forms of GIP, is associated with significant antihyperglycaemic activity in spontaneous obesity-diabetes. Biochem. J. 367: 913-920
56. Gault, V. A., O'Harte, F. P. M., Harriott, P., Flatt, P. R. (2002c) Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide. Biochem. Biophys. Res. Commun. 290: 1420-1426
57. Gault, V. A., Harriott, P., Flatt, P. R., O'Harte, F. P. M. (2002d) Cyclic AMP production and insulin releasing activity of synthetic fragment peptides of glucose-dependent insulinotropic polypeptide. Biosci. Rep. 22: 523-528
58. Gault, V. A., Flatt, P. R., O'Harte, F. P. M. (2003a) Glucose-dependent insulinotropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes. Biochem. Biophys. Res. Commun. 308: 207-213
59. 2-substituted analogues of glucose-dependent insulinotropic polypeptide. J. Endocrinol. 176: 133-141
60. 3)GIP antagonist and exendin(9-39) amide on GIP and GLP-1 induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: Evidence that GIP is the major physiological incretin. Diabetologia 46: 222-230
61. Gilon, P., Henquin, J. C. (2001) Mechanism and physiological significance of the cholinergic control of pancreatic beta cell function. Endocr. Rev. 22: 565-604
62. Graham, T. E., Sathasivam, P., Rowland, M., Marko, N., Greer, F., Battram, D. (2001) Caffeine ingestion elevates plasma insulin response in humans during an oral glucose tolerance test. Can. J. Physiol. Pharmacol. 79: 559-566
63. Green, B. D., Gault, V. A., Mooney, M. H., Irwin, N., Bailey, C. J., Harriott, P., Greer, B., Flatt, P. R., O'Harte, F. P. M. (2003a) Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1 . Biol. Chem. 384: 1543-1551
64. Green, B. D., Gault, V. A., Mooney, M. H., Irwin, N., Bailey, C. J., Harriott, P., Greer, B., Flatt, P. R., O'Harte, F. P. M. (2003b) Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1(7-36)amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivo. J. Mol. Endocrinol. 31: 529-540
65. 8-substituted GLP-1 analogues. Biol. Chem. 385: 169-177
66. 7-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity. J. Endocrinol. 180: 379-388
67. 9 substitution in glucagon-like peptide-1(7-36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9-36)amide and exendin (9-39). Metabolism 53: 252-259
68. Gribble, F. M., Reimann, F. (2002) Pharmacological modulation of K(ATP) channels. Biochem. Soc. Trans. 30: 333-339
69. Grill, V., Cerasi, E. (1973) Activation by glucose of adenyl cyclase in pancreatic islets of the rat. FEBS Lett. 33: 311-314
70. Guenifi, A., Portela-Gomes, G. M., Grimelius, L., Efendic, S., Abdel-Halim, S. M. (2000) Adenylyl cyclase isoform expression in non-diabetic and diabetic Goto-Kakizaki (GK) rat pancreas. Evidence for distinct overexpression of type-8 adenylyl cyclase in diabetic GK rat islets. Histochem. Cell Biol. 113: 81-89
71. Gutniak, M., Orskov, C., Holst, J. J., Ahren, B., Efendic, S. (1992) Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N. Engl. J. Med. 326: 1316-1322
72. Han, P., Werber, J., Surana, M., Fleischer, N., Michaeli, T. (1999) The calcium/calmodulin-dependent phosphodiesterase PDE1C down-regulates glucose-induced insulin secretion. J. Biol. Chem. 274: 22337-22344
73. 7 is crucial for GLP-1 action. Endocr. J. 44: 701-705
74. Harndähl, L., Jing, X. J., Ivarsson, R., Degerman, E., Ahren, B., Manganiello, V. C., Renstrom, E., Holst, L. S. (2002) Important role of phosphodiesterase 3B for the stimulatory action of cAMP on pancreatic beta-cell exocytosis and release of insulin. J. Biol. Chem. 277: 37446-37455
75. Harndähl, L., Wierup, N., Enerback, S., Mulder, H., Manganiello, V. C., Sundler, F., Degerman, E., Ahren, B., Holst, L. S. (2004) Beta-cell-targeted over-expression of phosphodiesterase 3B in mice causes impaired insulin secretion, glucose intolerance, and deranged islet morphology. J. Biol. Chem. 279: 15214-15222
76. Harrison, S. A., Reifsnyder, D. H., Gallis, B., Cadd, G. G., Beavo, J. A. (1986) Isolation and characterization of bovine cardiac muscle cGMP-inhibited phosphodiesterase: a receptor for new cardiotonic drugs. Mol. Pharmacol. 29: 506-514
77. Hendrick, G. K., Gjinovci, A., Baxter, L. A., Mojsov, S., Wollheim, C. B., Habener, J. F., Weir, G. C. (1993) Glucagon-like peptide-I-(7-37) suppresses hyperglycemia in rats. Metabolism 42: 1-6
78. Hinke, S. A., Manhart, S., Pamir, N., Demuth, H., Gelling, R. W., Pederson, R. A., McIntosh, C. H. (2001) Identification of a bioactive domain in the amino-termmus of glucose-dependent insulinotropic polypeptide (GIP). Biochim. Biophys. Ada. 1547: 143-155
79. 2]glucose-dependent insulinotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats. Diabetes 51: 656-661
80. Hinke, S. A., Manhart, S., Kühn-Wache, K., Nian, C., Demuth, H. U., Pederson, R. A., McIntosh, C. H. (2004) [Ser2]- and [SerP2] incretin analogs: comparison of dipeptidyl peptidase IV resistance and biological activities in vitro and in vivo. J. Biol. Chem. 279: 3998-4006
81. Holst, J. J. (1999) Glucagon-like peptide-1, a gastrointestinal hormone with a pharmaceutical potential. Curr. Med. Chem. 6: 1005-1017
82. Holst, J. J. (2003) Implementation of GLP-1 based therapy of type 2 diabetes mellitus using DPP-IV inhibitors. Adv. Exp. Med. Biol. 524: 263-279
83. Holst, J. J. (2004) Treatment of Type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors. Expert Opin. Emerg. Drugs 9: 155-166
84. Holst, J. J., Orskov, C., Nielsen, O. V., Schwartz, T. W. (1987) Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut. FEBS Lett. 211: 169-174
85. Holz, G. G. (2004) Epac: A new cAMP-binding protein in support of glucagon-like peptide-1 receptor-mediated signal transduction in the pancreatic beta-cell. Diabetes 53: 5-13
86. Holz, G. G., Habener, J. F. (1992) Signal transduction crosstalk in the endocrine system: pancreatic beta-cells and the glucose competence concept. Trends Biochem. Sci. 17: 388-393
87. Holz, G. G., Chepurny, O. G. (2003) Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus. Curr. Med. Chem. 10: 2471-2483
88. 2+ by activation of ryanodine receptors in glucagon-like peptide-1-(7-37). J. Biol. Chem. 274: 14147-14156
89. Houslay, M. D. (1998) Adaptation in cyclic AMP signalling processes: a central role for cyclic AMP phosphodiesterases. Semin. Cell Dev. Biol. 9: 161-167
90. Howell, S. L., Jones, P. M., Persaud, S. J. (1994) Regulation of insulin secretion: the role of second messengers. Diabetologia 37(Suppl. 2): S30-S35
91. Hui, H., Wright, C., Perfetti, R. (2001) Glucagon-like peptide 1 induces differentiation of islet duodenal homeobox-1-positive pancreatic ductal cells into insulin-secreting cells. Diabetes 50: 785-796
92. Huypens, P., Ling, Z., Pipeleers, D., Schuit, F. (2000) Glucagon receptors on human islet cells contribute to glucose competence of insulin release. Diabetologia. 43: 1012-1019
93. Islam, M. S., Leibiger, I., Leibiger, B., Rossi, D., Sorrentino, V., Ekstrom, T. J., Westerblad, H., Andrade, F. H., Berggren, P. O. (1998) In situ activation of the type 2 ryanodine receptor in pancreatic beta cells requires cAMP-dependent phosphorylation. Proc. Natl. Acad. Sci. USA 95: 6145-6150
94. Jonas, J. C., Laybutt, D. R., Steil, G. M., Trivedi, R, Pertusa, J. G., Van de Casteele, M., Weir, G. C., Henquin, J. C. (2001) High glucose stimulates early response gene c-Myc expression in rat pancreatic beta cells. J. Biol. Chem. 276: 35375-35381
95. Juhan-Vague, I., Alessi, M. C. (1997) PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb. Haemost. 78: 656-660
96. Kahn, S. E. (2003) The relative contribution of insulin resistance and beta cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 46: 3-19
97. Kaminski, A., Morgan, N. G. (2004) Expression of protein kinase G and cGMP-phosphodiesterase isoforms in pancreatic β-cells and investigation of the roles of these enzymes in control of cell viability. Diabetologia 47(Suppl. 1): A180
98. 2+ release in INS-1 pancreatic beta-cells. J. Physiol. 536: 375-385
99. 2+ release and exocytosis in pancreatic beta-cells. J. Biol. Chem. 278: 8279-8285
100. 2+ channels in rat islet beta-cells. Pflugers Arch. 435: 578-580
101. Kashima, Y., Miki, T., Shibasaki, T., Ozaki, N., Miyazaki, M., Yano, H., Seino, S. (2001) Critical role of cAMP-GEFII-Rim2 complex in incretin-potentiated insulin secretion. J. Biol. Chem. 276: 46046-46053
102. Kim, J. G., Baggio, L. L., Bridon, D. P., Castaigne, J. P., Robitaille, M. F., Jette, L., Benquet, C., Drucker, D. J. (2003) Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo. Diabetes 52: 751-759
103. Knapper, J. M., Puddicombe, S. M., Morgan, L. M., Fletcher, J. M. (1995) Investigations into the actions of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1(7-36) amide on lipoprotein lipase activity in explants of rat adipose tissue. J. Nutr. 125:183-188
104. Knudsen, L. B., Nielsen, P. F., Huusfeldt, P. O., Johansen, N. L., Madsen, K., Pedersen, F. Z., Thogersen, H., Wilken, M., Agerso, H. (2000) Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J. Med. Chem. 43: 1664-1669
105. Komatsu, R., Matsuyama, T, Namba, M., Watanabe, N., Itoh, H., Kono, N., Tarui, S. (1989) Glucagonostatic and insulinotropic action of glucagon like peptide I-(7-36)-amide. Diabetes 38: 902-905
106. Kopperud, R., Krakstad, C., Selheim, F., Doskeland, S. O. (2003) cAMP effector mechanisms. Novel twists for an 'old' signaling system. FEBS Lett. 546: 121-126
107. Kreymann, B., Williams, G., Ghatei, M. A., Bloom, S. R. (1987) Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 2: 1300-1304
108. Kühn-Wache, K., Manhart, S., Hoffmann, T., Hinke, S. A., Gelling, R., Pederson, R. A., McIntosh, C. H. S., Demuth, H.-U. (2000) Synthesis of analogs of glucose-dependent insulinotropic polypeptide with increased dipeptidyl peptidase IV resistance. Adv. Exp. Med. Biol. 477: 187-195
109. Leech, C. A., Castonguay, M. A., Habener, J. F. (1999) Expression of adenylyl cyclase subtypes in pancreatic beta-cells. Biochem. Biophys. Res. Commun. 254: 703-706
110. Lester, L. B., Langenberg, L. K., Scott, J. D. (1997) Anchoring of protein kinase A facilitates hormone-mediated insulin secretion. Proc. Natl. Acad. Sci. USA 94: 14942-14947
111. Liang, L., Beshay, E., Prud'homme, G. J. (1998) The phosphodiesterase inhibitors pentoxifylline and rolipram prevent diabetes in NOD mice. Diabetes 47: 570-575
112. Lipson, L. G., Oldham, S. B. (1983) The role of calmodulin in insulin secretion: the presence of a calmodulin-stimulatable phosphodiesterase in pancreatic islets of normal and pregnant rats. Life Sci. 32: 775-780
113. Liu, H., Maurice, D. H. (1998) Expression of cyclic GMP-inhibited phosphodiesterases 3A and 3B (PDE3A and PDE3B) in rat tissues: differential subcellular localization and regulated expression by cyclic AMP. Br. J. Pharmacol. 125: 1501-1510
114. Loweth, A. C., Williams, G. T., Scarpello, J. H., Morgan, N. G. (1996) Heterotrimeric G-proteins are implicated in the regulation of apoptosis in pancreatic beta-cells. Exp. Cell. Res. 229: 69-76
115. Lund, P. K., Goodman, R. H., Dee, P. C., Habener, J. F. (1982) Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem. Proc. Natl. Acad. Sci. USA 79: 345-349
116. MacIntosh, C. G., Horowitz, M., Verhagen, M. A., Smout, A. J., Wishart, J., Morris, H., Goble, E., Morley, J. E., Chapman, I. M. (2001) Effect of small intestinal nutrient infusion on appetite, gastrointestinal hormone release, and gastric myoelectrical activity in young and older men. Am. J. Gastroenterol. 96: 997-1007
117. Manhart, S., Hinke, S. A., McIntosh, C. H., Pederson, R. A., Demuth, H. U. (2003) Structure-function analysis of a series of novel GIP analogues containing different helical length linkers. Biochemistry 42: 3081-3088
118. Mehats, C., Andersen, C. B., Filopanti, M. (2002) Cyclic nucleotide phosphodiesterases and their role in endocrine cell signaling. Trends Endocrinol. Metab. 13: 29-35
119. Meier, J. J., Gallwitz, B., Salmen, S., Goetze, O., Holst, J. J., Schmidt, W. E., Nauck, M. A. (2003) Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 88: 2719-2725
120. Meneilly, G. S., Greig, N., Tildesley, H., Habener, J. F., Egan, J. M., Elahi, D. (2003) Effects of 3 months of continuous subcutaneous administration of glucagon-like peptide 1 in elderly patients with type 2 diabetes. Diabetes Care 26: 2835-2841
121. Mentlein, R. (1999) Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul. Pept. 85: 9-24
122. Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S, Oku, A., Tsuda, K., Toyokuni, S., Hiai, H., Mizunoya, W., Fushiki, T., Holst, J. J., Makino, M., Tashita, A., Kobara, Y., Tsubamoto, Y., Jinnouchi, T., Jomori, T., Seino, Y. (2002) Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat. Med. 8: 738-742
123. Mojsov, S., Weir, G. C., Habener, J. F. (1987) Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J. Clin. Invest. 79: 616-619
124. Nielsen, L. L., Young, A. A., Parkes, D. G. (2004) Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul. Pept. 117: 77-88
125. Oben, J., Morgan, L. M., Fletcher, J., Marks, V. (1991) Effect of the entero-pancreatic hormones, gastric inhibitory polypeptide and glucagon-like polypeptide-1(7-36) amide, on fatty acid synthesis in explants of rat adipose tissue. J. Endocrinol. 130: 267-272
126. O'Harte, F. P. M., Gray, A. M., Abdel-Wahab, Y. H., Flatt, P. R. (1997) Effects of non-glycated and glycated glucagon-like peptide-1(7-36) amide on glucose metabolism in isolated mouse abdominal muscle. Peptides 18: 1327-1333
127. O'Harte, F. P. M., Abdel-Wahab, Y. H. A., Conlon, J. M., Flatt, P. R. (1998) Amino terminal glycation of gastric inhibitory polypeptide enhances its insulinotropic action on clonal pancreatic B-cells. Biochim. Biophys. Acta 1425: 319-327
128. O'Harte, F. P. M., Mooney, M. H., Flatt, P. R. (1999) N-terminally modified gastric inhibitory polypeptide exhibits aminopeptidase resistance and enhanced antihyperglycaemic activity. Diabetes 48: 758-765
129. O'Harte, F. P. M., Mooney, M. H., Kelly, C. M. N., Flatt, P. R. (2000a) Improved glycaemic control in obese diabetic ob/ob mice using N-terminally modified gastric inhibitory polypeptide. J. Endocrinol. 165: 639-648
130. O'Harte, F. P. M., Mooney, M. H., Lawlor, A., Flatt, P. R. (2000b) N-terminally modified glucagon-like peptide-1(7-36) amide exhibits resistance to enzymatic degradation while maintaining its antihyperglycaemic activity in vivo. Biochim. Biophys. Acta 1474: 13-22
131. O'Harte, F. P. M., Mooney, M. H., Kelly, C. M., McKillop, A. M., Flatt, P. R. (2001) Degradation and glycemic effects of His(7)-glucitol glucagon-like peptide-1(7-36)amide in obese diabetic ob/ob mice. Regul. Pept. 96: 95-104
132. O'Harte, F. P. M., Gault, V. A., Parker, J. C., Harriott, P., Mooney, M. H., Bailey, C. J., Flatt, P. R. (2002) Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of glucose-dependent insulinotropic polypeptide: N-acetyl-GIP and pGlu-GIP. Diabetologia 45: 1281-1291
133. Packer, M., Carver, J. R., Rodeheffer, R. J., Ivanhoe, R. J., DiBianco, R., Zeldis, S. M., Hendrix, G. H., Bommer, W. J., Elkayam, U., Kukin, M. L., Mallis, G. I., Solao, J. A., Shannon, J., Tandon, P. K., DeMets, D. L. (1991) Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N. Engl. J. Med. 325: 1468-1475
134. Parker, J. C., Van Volkenberg, M. A., Ketchum, R. J., Brayman, K. L., Andrews, K. M. (1995) Cyclic AMP phosphodiesterases of human and rat islets of Langerhans: contributions of types III and IV to the modulation of insulin secretion. Biochem. Biophys. Res. Commun. 217: 916-923
135. Parker, J. C., VanVolkenburg, M. A., Nardone, N. A. (1997) Modulation of insulin secretion and glycemia by selective inhibition of cyclic AMP phosphodiesterase III. Biochem. Biophys. Res. Commun. 236: 665-669
136. Pauly, R. P., Demuth, H. U., Rosche, F., Schmidt, J., White, H. A., Lynn, F., McIntosh, C. H., Pederson, R. A. (1999) Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor Ile-thiazolidide. Metabolism 48: 385-389
137. Pederson, R. A., White, H. A., Schlenzig, D., Pauly, R. P., McIntosh, C. H., Demuth, H. U. (1998a) Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. Diabetes 47: 1253-1258
138. Pederson, R. A., Satkunarajah, M., McIntosh, C. H., Scrocchi, L. A., Flamez, D., Schuit, F., Drucker, D. J., Wheeler, M. B. (1998b) Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor -/- mice. Diabetes 47: 1046-1052
139. Perfetti, R., Zhou, J., Doyle, M. E., Egan, J. M. (2000) Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology 141: 4600-4605
140. Perry, M. J., Higgs, G. A. (1998) Chemotherapeutic potential of phosphodiesterase inhibitors. Curr. Opin. Chem. Biol. 2: 472-481
141. Persaud, S. J., Jones, P. M., Howell, S. L. (1990) Glucose-stimulated insulin secretion is not dependent on activation of protein kinase A. Biochem. Biophys. Res. Commun. 173: 833-839
142. Peterhoff, M., Sieg, A., Brede, M., Chao, C.M., Hein, L., Ullrich, S. (2003) Inhibition of insulin secretion via distinct signaling pathways in alpha2-adrenoceptor knockout mice. Eur J Endocrinol. 149: 343-350
143. Pittler, S. J., Baehr, W., Wasmuth, J. J., McConnell, D. G., Champagne, M. S., vanTuinen, P., Ledbetter, D., Davis, R. L. (1990) Molecular characterization of human and bovine rod photoreceptor cGMP phosphodiesterase alpha-subunit and chromosomal localization of the human gene. Genomics 6: 272-283
144. Porte, D., Kahn, S. E. (2001) Beta-cell dysfunction and failure in type 2 diabetes: potential mechanisms. Diabetes 50(Suppl. 1): S160-S163
145. Pospisilik, J. A., Stafford, S. G., Demuth, H. U., Brownsey, R., Parkhouse, W., Finegood, D. T., McIntosh, C. H., Pederson, R. A. (2002a) Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats. Diabetes 51: 943-950
146. Pospisilik, J. A., Stafford, S. G., Demuth, H. U., McIntosh, C. H., Pederson, R. A. (2002b) Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: a euglycemic-hyperinsulinemic clamp study. Diabetes 51: 2677-2683
147. Pospisilik, J. A., Martin, J., Doty, T., Ehses, J. A., Pamir, N., Lynn, F. C., Piteau, S., Demuth, H. U., McIntosh, C. H., Pederson, R. A. (2003) Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes 52: 741-750
148. Preitner, F., Ibberson, M., Franklin, I., Binnert, C., Pende, M., Gjinovci, A., Hansotia, T., Drucker, D. J., Wollheim, C., Burcelin, R., Thorens, B. (2004) Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-I and GIP receptors. J. Clin. Invest. 113: 635-645
149. Purrello, F., Rabuazzo, A. M. (2000) Metabolic factors that affect beta-cell function and survival. Diabetes Nutr. Metab. 13: 84-91
150. Pyne, N. J., Cooper, M. E., Houslay, M. D. (1987) The insulin-and glucagon-stimulated 'dense-vesicle' high-affinity cyclic AMP phosphodiesterase from rat liver. Purification, characterization and inhibitor sensitivity. Biochem. J. 242: 33-42
151. Reinhardt, R. R., Chin, E., Zhou, J., Taira, M., Murata, T., Manganiello, V. C., Bondy, C. A. (1995) Distinctive anatomical patterns of gene expression for cGMP-inhibited cyclic nucleotide phosphodiesterases. J. Clin. Invest. 95: 1528-1538
152. Renstrom, E., Eliasson, L., Rorsman, P. (1997) Protein kinase A-dependent and independent stimulation of exocytosis by cAMP in mouse pancreatic B-cells. J. Physiol. 502: 105-118
153. Ritzel, U., Leonhardt, U., Ottleben, M., Ruhmann, A, Eckart, K., Spiess, J., Ramadori, G. (1998) A synthetic glucagon-like peptide-1 analog with improved plasma stability. J. Endocrinol. 159: 93-102
154. Rolin, B., Larsen, M. O., Gotfredsen, C. F., Deacon, C. F., Carr, R. D., Wilken, M., Knudsen, L. B. (2002) The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. Am. J. Physiol. Endocrinol. Metab. 283: E754-E752
155. Ruiz-Grande, C., Pintado, J., Alarcon, C., Castilla, C., Valverde, L, Lopez-Novoa, J. M. (1990) Renal catabolism of human glucagon-like peptides 1 and 2. Can. J. Physiol. Pharmacol. 68: 1568-1573
156. Schuit, F. C. (1996) Factors determining the glucose sensitivity and glucose responsiveness of pancreatic beta cells. Horm. Res. 46: 99-106
157. Scrocchi, L. A., Marshall, B. A., Cook, S. M., Brubaker, P. L., Drucker, D. J. (1998) Identification of glucagon-like peptide 1 (GLP-1) actions essential for glucose homeostasis in mice with disruption of GLP-1 receptor signaling. Diabetes 47: 632-639
158. Shafiee-Nick, R., James, R. F. L., London, N. J. M., Pyne, N. J., Furman, B. L. (1994) Cyclic 3′5′ AMP phosphodiesterases in human islets. Diabetic Med. 11 (Suppl 1): S31
159. Shafiee-Nick, R., Pyne, N. J., Furman, B. L. (1995) Effects of type-selective phosphodiesterase inhibitors on glucose-induced insulin secretion and islet phosphodiesterase activity. Br. J. Pharmacol. 115: 1486-1492
160. Sharp, G. W. (1979) The adenylate cyclase-cyclic AMP system in islets of Langerhans and its role in the control of insulin release. Diabetologia 16: 287-296
161. Siegel, E. G., Gallwitz, B., Scharf, G., Mentlein, R., Morys-Wortmann, C., Folsch, U. R., Schrezenmeir, J., Drescher, K., Schmidt, W. E. (1999a) Biological activity of GLP-1-analogues with N-terminal modifications. ReguL Pept. 79: 93-102
162. Siegel, E. G., Scharf, G., Gallwitz, B., Mentlein, R., Morys-Wortmann, C., Folsch, U. R., Schmidt, W. E. (1999b) Comparison of the effect of native glucagon-like peptide 1 and dipeptidyl peptidase IV-resistant analogues on insulin release from rat pancreatic islets. Eur. J. Clin. Invest. 29: 610-614
163. Skoglund, G., Hussain, M. A., Holz, G. G. (2000) Glucagon-like peptide 1 stimulates insulin gene promoter activity by protein kinase A-independent activation of the rat insulin I gene cAMP response element. Diabetes 49: 1156-1164
164. Soderling, S. H., Beavo, J. A. (2000) Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. Curr. Opin. Cell Biol. 12: 174-179
165. Sudre, B., Broqua, P., White, R. B., Ashworth, D., Evans, D. M., Haigh, R., Junien, J. L., Aubert, M. L. (2002) Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male zucker diabetic fatty rats. Diabetes 51: 1461-1469
166. 2+, calmodulin and trifluoperazine. Biochem. J. 197: 459-464
167. Susini, S., Roche, E., Prentki, M., Schlegel, W. (1998) Glucose and glucoincretin peptides synergize to induce c-fos, c-jun, junB, zif-268, and nur-77 gene expression in pancreatic beta(INS-1) cells. FASEB J. 12: 1173-1182
168. The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329: 977-986
169. Thorens, B. (1992) Expression cloning of the pancreatic beta-cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc. Natl. Acad. Sci. USA 89: 8641-8645
170. Torphy, T. J. (1998) Phosphodiesterase isozymes. Molecular targets for novel antiasthma agents. Am. J. Respir. Crit. Care Med. 157:351-370
171. Trumper, A., Trumper, K., Trusheim, H., Arnold, R., Göke, B., Horsch, D. (2001) Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling. Mol. Endocrinol. 15: 1559-1570
172. Tseng, C. C., Jarboe, L. A., Wolfe, M. M. (1994) Regulation of glucose-dependent insulinotropic peptide gene expression by a glucose meal. Am. J. Physiol. 266: G887-G891
173. Turner, R. C. (1998) The U.K. Prospective Diabetes Study. A review. Diabetes Care 21 (Suppl 3): C35-C38
174. Usdin, T. B., Mezey, E., Button, D. C., Brownstein, M. J., Bonner, T. I. (1993) Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. Endocrinology 133: 2861-2870
175. Valverde, I., Morales, M., Clemente, F., Lopez-Delgado, M. I., Delgado, E., Perea, A., Villanueva-Penacarrillo, M. L. (1994) Glucagon-like peptide 1: a potent glycogenic hormone. FEBS Lett. 349: 313-316
176. Villanueva-Penacarrillo, M. L., Alcantara, A. I., Clemente, F., Delgado, E., Valverde, I. (1994) Potent glycogenic effect of GLP-1(7-36)amide in rat skeletal muscle. Diabetologia 37: 1163-1166
177. Vilsboll, T., Holst, J. J. (2004) Incretins, insulin secretion and Type 2 diabetes mellitus. Diabetologia 47: 357-366
178. Wang, X., Zhou, J., Doyle, M. E., Egan, J. M. (2001) Glucagon-like peptide-1 causes pancreatic duodenal homeobox-1 protein translocation from the cytoplasm to the nucleus of pancreatic beta-cells by a cyclic adenosine monophosphate/protein kinase A-dependent mechanism. Endocrinology 142: 1820-1827
179. Wang, Y., Montrose-Rafizadeh, C., Adams, L., Raygada, M., Nadiv, O., Egan, J. M. (1996) GIP regulates glucose transporters, hexokinases, and glucose-induced insulin secretion in RIN 1046-38 cells. Mol. Cell Endocrinol. 116: 81-87
180. Weir, G. C., Mojsov, S., Hendrick, G. K., Habener, J. F. (1989) Glucagon like peptide I (7-37) actions on endocrine pancreas. Diabetes 38: 338-342
181. Xiao, Q., Giguere, J., Parisien, M., Jeng, W., St Pierre, S. A., Brubaker, P. L., Wheeler, M. B. (2001) Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo. Biochemistry 40: 2860-2869
182. Yan, C., Zhao, A. Z., Bentley, J. K., Loughney, K., Ferguson, K., Beavo, J. A. (1995) Molecular cloning and characterization of a calmodulin-dependent phosphodiesterase enriched in olfactory sensory neurons. Proc. Nat. Acad. Sci. USA 92: 9677-9681
183. Yaney, G. C., Civelek, V. N., Richard, A. M., Dillon, J. S., Deeney, J. T., Hamilton, J. A., Korchak, H. M., Tornheim, K., Corkey, B. E., Boyd, A. E. 3rd (2001) Glucagon-like peptide 1 stimulates lipolysis in clonal pancreatic beta-cells (HIT). Diabetes 50: 56-62
184. Yip, R. G., Boylan, M. O., Kieffer, T. J., Wolfe, M. M. (1998) Functional GIP receptors are present on adipocytes. Endocrinology 139: 4004-4007
185. Zhao, A. Z., Zhao, H., Teague, J., Fujimoto, W., Beavo, J. A. (1997) Attenuation of insulin secretion by insulin-like growth factor 1 is mediated through activation of phosphodiesterase 3B. Proc. Natl. Acad. Sci. USA 94: 3223-3228
186. Zhou, J., Wang, X., Pineyro, M. Á., Egan, J. M. (1999) Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells. Diabetes 48: 2358-2366